New Intermediate Nail and RC Lag Screw Expand Gamma4 Portfolio to Meet the Needs of Surgeons and Their Patients
- None.
- None.
Insights
The expansion of Stryker's Gamma4 Hip Fracture Nailing System, particularly with the introduction of the RC Lag Screw and anti-rotation clip with sleeve components, represents a significant advancement in orthopaedic surgical tools. The adoption rate, with over 19,000 cases at more than 850 facilities, indicates strong market acceptance. This can be attributed to the system's versatility in treating various types of femur fractures and its potential to improve procedural efficiency.
The medical device industry is highly competitive and innovation is a key driver for growth. Stryker's ability to innovate and expand its product portfolio could potentially increase its market share in the orthopaedic segment. However, it is important to monitor the long-term clinical outcomes and cost-effectiveness of the Gamma4 System to fully assess its impact on Stryker's financial performance.
The introduction of new components to an existing medical system like Stryker's Gamma4 is a strategic move that can lead to an increase in sales within the existing customer base and potentially attract new customers. It is indicative of Stryker's commitment to continuous improvement and could lead to a stronger brand reputation among orthopaedic surgeons.
From a market perspective, the aging global population and the prevalence of conditions like osteoporosis are likely to drive demand for hip fracture solutions. This demographic trend could provide a tailwind for Stryker's Trauma business segment. The company's performance in this area should be closely watched by investors as it may contribute significantly to Stryker's overall growth.
The Gamma4 Hip Fracture Nailing System's design, aimed at stabilizing fractures and correcting bone deformities, is critical in orthopaedic surgery. The system's adaptability to both osteoporotic and osteopenic bone is particularly relevant, as these conditions are common in elderly patients who are at a high risk of hip fractures.
With the addition of the RC Lag Screw and anti-rotation clip, surgeons may achieve better outcomes through enhanced fixation and stability during procedures. This can potentially lead to reduced operation times and improved recovery rates for patients. These clinical benefits, if substantiated through peer-reviewed studies, could reinforce the system's value proposition and justify its adoption despite any premium pricing.
Stryker’s Gamma4 Hip Fracture Nailing System Used in Over 19,000 Cases Since Launch
Stryker's Gamma4 System is indicated for the treatment of stable and unstable fractures, as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone). (Photo: Business Wire)
"The Gamma4 System, with its rich 30-year legacy of innovation and clinical history, has ushered in a new era of intramedullary nailing systems for hip fractures,” said Eric Tamweber, Vice President and General Manager, Stryker’s Trauma business. “Stryker remains unwavering in our commitment to providing cutting-edge orthopaedic solutions to meet the needs of our customers. While Gamma4 has already made a significant impact, the new line extension expands our nailing portfolio and provides surgeons with options that are designed to streamline operative flow and improve procedural efficiency.”
The Gamma4 System, which launched in 2022, is indicated for the treatment of stable and unstable fractures, as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone). The recent line extension, including the Gamma4 intermediate nail and RC Lag Screw, received 510(k) clearance in June 2023. Key features include:
-
Increased cutout resistance: The Gamma4 RC Lag Screw increases cutout resistance by
15% compared to the standard Gamma4 lag screw.1,2 - Increased fixation: The RC lag screw blades allow for 2mm of additional surface area contact within the femoral head compared to the standard Gamma4 lag screw.3
- New intermediate nail option: Designed to provide more isthmus support than a trochanteric nail and faster procedural time compared to a long nail.3,4
- Controlling intraoperative rotation: The anti-rotation clip and sleeve components provide intraoperative stability in rotationally unstable femoral head neck fragments.
“The Gamma4 Phase 2 launch of the intermediate nail, RC lag screw, and anti-rotation clip is sure to provide additional support to surgeons for treatment of challenging hip fractures,” said Dr. Sanjit Konda, Director of Trauma at NYU Langone Orthopedics and Jamaica Hospital Medical Center, and Chairman of Orthopedic Surgery at MediSys Health Network. “Intertrochanteric hip fractures with subtrochanteric extension can now be treated with a distally targeted intermediate nail. Hip fractures with involvement of the basicervical neck region can be provisionally stabilized with the anti-rotation clip and sleeve during lag screw insertion. The Phase 2 launch of these additional Gamma4 features will expand the surgeon's toolbox and add to an already best-of-class nailing system.”
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Dr. Sanjit Konda is a paid consultant of Stryker Trauma and Extremities. The opinions expressed by Dr. Sanjit Konda are those of Dr. Sanjit Konda and not necessarily those of Stryker. Individual experiences may vary.
A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area.
G4-FL-2, 11-2023
References
- Internal Report № D0000093463, Rev AC, Schönkirchen, Germany
-
Internal Report № D0000245312, Rev AE, Schönkirchen,
Germany - G4-ST-1, Rev-3, 07-2023
- Internal Report № D0000250608. Rev AA, Schönkirchen, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117805597/en/
Andrea Sampson
President/CEO, Sampson Public Relations Group
asampson@sampsonprgroup.com
562.304.0301
Source: Stryker
FAQ
How many cases has the Gamma4 System been used in since its launch?
What regions of the femur is the Gamma4 System indicated for?
What components have been added to the Gamma4 System?
Who is the Vice President and General Manager of Stryker's Trauma business?
